Company

MedCision is the world leader in next-generation automated cell thawing for advanced therapies. The company develops and commercializes technologies that automate and standardize vital preclinical and clinical biologics handling for critical post-manufacturing processes. MedCision’s digitally enabled ThawSTAR® Automated Cell Thawing Systems are designed to replace uncontrolled and highly variable manual methods, de-risking the therapeutic cell thawing process and optimizing cell efficacy. An industry first, ThawSTAR systems optimize cell thawing using a customizable algorithm for each unique cell therapy product and protocol. These systems, combined with MedCision’s ultra-low temperature cold storage and transport solutions, advance near-patient drug management by providing controlled and scalable processing of temperature-sensitive biotherapeutic products.

  • MANAGEMENT TEAM
  • BOARD OF DIRECTORS
  • ADVISORY BOARD

Management Team


Rolf

Rolf Ehrhardt, MD, PhD

President and Chief Executive Officer

After 10 years growing BioCision into the leading provider of temperature-sensitive sample and drug handling solutions, Dr. Rolf Ehrhardt established MedCision in 2016 in order to focus efforts specifically on the automation of pre-clinical and clinical processes. Dr. Ehrhardt has more than 25 years of experience in leadership and innovation in medical research and product development. Prior to these endeavors, he was responsible for the early (phase 1a) clinical development of a novel HCV protease inhibitor at Intermune. Before that, Dr. Ehrhardt was the vice president of preclinical development at Corgentech. He was the founding president of BioSeek, where he raised close to $20 million in private financing. Prior to founding BioSeek, Dr. Ehrhardt led a scientific group focused on new target discovery and immuno-therapeutics development at Protein Design Labs (now PDL BioPharma Inc.). Dr. Ehrhardt was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty Fellow at the National Institutes of Health, where his focus was on mucosal immunology and inflammatory bowel disease. He has authored more than 40 peer reviewed publications and holds multiple patents. Dr. Ehrhardt earned his M.D. and Ph.D. with distinction from the Technical University of Munich, Germany.


Ron

Ron DiNocco

Chief Financial Officer and Head of Corporate Development

Mr. DiNocco manages corporate finance development with responsibility for long term capital strategy and investor relations. From 2000-2008 he served multiple leadership roles at Akiva Corporation, including CFO and CEO, while achieving global expansion through new customer and government relationships. During this time, Mr. DiNocco was able to successfully close an institutional Series A round and negotiated the acquisition of a division of O’Reilly and Associates. He holds a bachelor’s degree from Babson College and has also completed International Business studies at the University of Monash in Australia. Mr. DiNocco serves on the board of Tech Coast Angels and is an active supporter of early stage companies.


Sam

Samuel Kent

Chief Commercial Officer

Mr. Kent has over 16 years of experience in sales, business development and marketing of a diverse portfolio of laboratory products and services. Prior to joining MedCision, Mr. Kent served in multiple senior roles at BioCision, Thermo Fisher Scientific and Parker Hannifin including Commercial Manager North America and Global Business Development Manager. In these positions, he was instrumental in expanding corporate presence and commercial success in the biotechnology, clinical chemistry, academic research and pharmaceutical markets. Mr. Kent graduated with his MBA from Colorado State University and his B.Sc from Northern Michigan University.


Brian

Brian Schryver

Chief Development Officer

With a 25-year career in molecular biological research and development, Mr. Schryver has extensive experience developing instruments and tooling for the life science field. Prior to co-founding BioCision in 2007, Mr. Schryver was a scientist at CFD Therapeutics Inc. and worked in topical formulation and assay development at Corgentech, now Anesiva. Mr. Schryver also was involved in preclinical development and biomarker research at SUGEN, and discovery research at Syntex.


Katerina

Katharina Hohenfellner, MD, PhD

Chief Medical Affairs Officer

Katharina Hohenfellner, MD, PhD is the Chief Medical Affairs Officer at MedCision. In her role she is responsible for facilitating the integration of MedCision’s standardization and automation products into GMP environments and clinical programs. Prof. Hohenfellner oversees the development of new clinical applications; and develops regional educational and research opportunities in partnership with key medical institutions, agencies and industry leaders. Dr. Hohenfellner is Board Certified in Pediatrics at the Children’s Hospital in Johannes Gutenberg-University, Germany. She has a Ph.D. and an M.D. from the University of Mainz. For more than 10 years, Dr. Hohenfeller served as an Associate Professor in the Department of Pediatrics at the University of Mainz and Salzburg. She is a Board Member of the Society of Pediatric Nephrologists.


Board of Directors

Rolf Ehrhardt, MD, PhD

After 10 years growing BioCision into the leading provider of temperature-sensitive sample and drug handling solutions, Dr. Rolf Ehrhardt established MedCision in 2016 in order to focus efforts specifically on the automation of pre-clinical and clinical processes. Dr. Ehrhardt has more than 25 years of experience in leadership and innovation in medical research and product development. Prior to these endeavors, he was responsible for the early (phase 1a) clinical development of a novel HCV protease inhibitor at Intermune. Before that, Dr. Ehrhardt was the vice president of preclinical development at Corgentech. He was the founding president of BioSeek, where he raised close to $20 million in private financing. Prior to founding BioSeek, Dr. Ehrhardt led a scientific group focused on new target discovery and immuno-therapeutics development at Protein Design Labs (now PDL BioPharma Inc.). Dr. Ehrhardt was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty Fellow at the National Institutes of Health, where his focus was on mucosal immunology and inflammatory bowel disease. He has authored more than 40 peer reviewed publications and holds multiple patents. Dr. Ehrhardt earned his M.D. and Ph.D. with distinction from the Technical University of Munich, Germany.


Blair W. Stewart

Mr. Stewart, a former corporate partner of Wilson, Sonsini, Goodrich & Rosati, has practiced corporate, securities and business law in Silicon Valley for more than 35 years, offering strategic business and legal advice to emerging biotechnology and high technology companies. He practiced at Wilson, Sonsini Goodrich & Rosati from 1976 to 2001, becoming a partner in 1983. Since 2001 he has conducted a private legal practice as well as co-founding an angel-investor and venture-capital-backed biotechnology company, now in clinical trials. He has advised both for-profit and non-profit companies in regulatory and corporate governance, and is experienced in public and private financings, mergers and acquisitions, intellectual property and licensing, and domestic and international joint ventures. Mr. Stewart holds a Doctor of Jurisprudence from Stanford Law School and a Bachelor of Science from the United States Naval Academy.


Paul Nowak

Mr. Nowak joined Biotix Holdings in April 2007. Prior to that, he was the Chief Operating Officer of Symyx Technologies, a Silicon Valley manufacturer of high-throughput robotics and developer of software applications for R&D. He spent the majority of his career (26 years) at VWR International, a global distributor of laboratory supplies where he held many positions during his tenure, including CEO and President. Mr. Nowak was one of the key leaders that transformed VWR into a $2.8 billion company.


Rodney Turner

Mr. Turner is a life sciences business development and marketing executive with over 25 years of global experience within the life science tools, diagnostic and pharmaceutical sectors. Most recently, he served as Vice President of Corporate Business Development at Life Technologies where he played a leading role in numerous acquisitions, as well as helping develop corporate strategy and launching new business segments. He has extensive experience in mergers and acquisitions, large-scale strategic collaborations, venture investment and R&D project management. Mr. Turner currently heads RWT Consulting, Inc and is a board member of AYOXXA Biosystems GmBH and Exiqon A/S.


Heiner Dreismann, PhD

Dr. Dreismann is a seasoned executive with more than 28 years of experience in the health care industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO, Roche Molecular Systems, Head of Global Business Development, Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Munster) in Germany.


Advisory Board

Wm. Andrew Heaton, MD

Former Chief Medical Officer for Novartis Diagnostics (Chiron)

Dr. Wm. Andrew Heaton is a Blood Banks and Biotechnology Consultant in the Bay Area. Previously Dr. Heaton was corporate head of Transfusion Services at NSLIJ Health System in the Pathology/Laboratory Medicine. Prior to that Dr. Heaton served as the Chief Medical Officer for Novartis Diagnostics (Chiron) where he as responsible for Clinical, Regulatory, and Scientific Affairs. Dr. Heaton also served as Chief Medical Officer of Blood Systems Inc. in San Francisco, CA, following the merger with Irwin Memorial Blood Centers where he had previously been President and CEO. Academic titles include Professor of Pathology at Hofstra NSLIJ Medical School, subsequent to that Professor of Laboratory Medicine at the University of California, San Francisco. Dr. Heaton is a graduate of medicine at Trinity College, Dublin University, and completed pathology training at the University of Cape Town in South Africa. Dr. Heaton is a US pathology/blood-banking specialist and has been a Fellow of the Royal College of Pathology, the South African College of Medicine, and the American Society of Clinical Pathology.


Anthony Davies, PhD

Dark Horse Consulting

Anthony Davies, PhD has 20 years experience in the cell and gene therapy field. He is currently the President of Dark Horse Consulting where he focuses on CMC and product development issues in cell and gene therapy. Previously Dr Davies held the position of Chief Technology Officer at Capricor Therapeutics, and led a large, randomized, placebo-controlled clinical trial for an allogeneic cardiac stem cell product. Prior to Capricor, Dr Davies served as VP, Product Development at Geron Corporation and was responsible for all cell therapies’ process and analytical science and manufacturing, including both autologous and allogeneic products.  He was schooled in the UK, obtaining a Masters Degree in Natural Sciences from the University of Cambridge and a PhD in Biochemical Engineering.

Hendrik H.C. Gienow

Former Managing Director of Eurohypo

Mr. Gienow is a veteran banker, who currently works as an advisor to family-owned and private equity businesses. He has spent 20 years as a Senior Executive at Eurohypo, at the time the leading European specialist bank for real estate and the public sector. In this role he was responsible for group strategy, development, global restructuring, and portfolio management. Mr. Gienow brings considerable experience and knowledge to the table in the areas of corporate development, mergers, and acquisition and post-merger integration. He has played key roles in several successful mergers, and built and led businesses in both Europe and Asia. Mr. Gienow served for 10 years as Chairman of Eurohypo Japan. He is also a Senior Advisor to PAG Group of Hong Kong. Mr. Gienow, who obtained a degree in law from Bonn University, started his career at Deutsche Bank. He attended the Advanced Management Program at the Wharton School of the University of Pennsylvania, and lectures on credit risk management at the University of Regensburg.


Lee Buckler, JD

President, CEO, Director at RepliCel Life Sciences Inc
Founder and Managing Director of the Cell Therapy Group

Mr. Buckler is President, CEO and Director at RepliCel Life Sciences, Inc. and brings broad experience consulting on business development strategies, competitive intelligence, market research and analysis, deal-making, marketing and communications, and sales-lead generation. He is also the founder of Cell Therapy News and Cell Therapy Blog, and serves on the editorial board of the journals BioProcess International and Regenerative Medicine. Before transitioning to biotech, Mr. Buckler earned a law degree from University of British Columbia and was a practicing commercial attorney.


Lori Kunkel, MD

Principal at D2D, LLC
Advisory Board Chair

Dr. Kunkel brings extensive experience in developing and commercializing oncologic and immunologic therapies, with over 20 years of executive responsibilities in industry including clinical, regulatory, medical affairs and licensing. As chief medical officer at Pharmacyclics, she was instrumental in achieving breakthrough designation for the company’s lead product, ibrutinib. Previously, Dr. Kunkel spent ten years in academic and clinical research and served as a faculty member in the Division of Hematology/Oncology Bone Marrow transplant unit at University of California, Los Angeles.


Vincent L. DiVito

Founder and Managing Director of Vincent L. DiVito, Inc.

Mr. DiVito is the owner and Managing Director of Vincent L. DiVito, Inc., a financial and management consulting firm. Previously, he spent 20 years with Lonza, a global life sciences company, and its predecessor (Alusuisse Lonza) which included Packaging and Aluminum businesses as well. In the latter part of that 20 year period Mr. DiVito was President of Lonza America, Inc., after having served as its Chief Financial Officer and Treasurer. Prior to that he was the Vice-President and Chief Financial Officer for Algroup Wheaton, a global pharmaceutical and cosmetics packaging company within Alusuisse Lonza. He currently serves on the boards of Entertainment Gaming Asia (NASDAQ) and AquaMetals (NASDAQ) where he chairs the Audit Committees and serves on the Compensation Committees as well as Elara Foodservice Disposables (a private company). Previously, he served on the board of Riviera Holdings (Amex) where he chaired the Audit Committee and served as non-executive chair through a change in control. Mr. DiVito is a certified public accountant and a certified management accountant as well as a NACD Board Leadership Fellow and is currently the President of the Long Island Chapter of Financial Executives International.